Small Biotech Exception from Medicare Drug Price Negotiation Program.
This bill aims to exempt small biotechnology companies that heavily invest in research and development from the Medicare drug price negotiation program. This means certain new drugs from these companies might not be subject to government price negotiations, potentially impacting drug availability and costs for seniors in the future.
Key points
Small biotech companies investing heavily in R&D may be exempt from Medicare drug price negotiations starting in 2029.
The exemption applies to companies with five or fewer drugs and a specific percentage of revenue dedicated to R&D.
If such a company is acquired by a larger manufacturer, the price negotiation exemption may be lost.
Introduced
Citizen Poll